Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:51:56.763Z.
Calculation as of: 2026-10-06T15:51:56.763Z.
Quote observation: 2026-10-06T15:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6608cd76dc650ef8b2fc8232603ca313d9f3e0951a45c9e65e7ec74b346396eb
PEG RATIO
N/A
Karyopharm Therapeutics Inc.
Market Cap
$14.96M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | $14.96M | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.03M | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.58M | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.60M | N/A |
| Pulsenmore Ltd. Ordinary Shares (PLSM)vs › | $14.37M | N/A |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.83M | N/A |
| BioCardia, Inc. (BCDA)vs › | $16.08M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.04M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.81M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
